Be careful not to discount the disease burden in women with axSpA.
Reference1. Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018;20:35. doi: 10.1007/s11926-018-0744-2.
Rusman and fellow researchers at the Amsterdam Rheumatology and Immunology Center in the Netherlands found that although men have worse radiologic prognosis in axial spondyloarthritis (axSpA), women have a higher disease burden that is multifactorial.1 Thumb through the slides for the details of the study and the take-home points for clinicians.
(Image credit: ©Africa Studio/Shutterstock.com)
axSpA, axial spondyloarthritis; TNFi, tumor necrosis factor inhibitor.
Traditionally, women have been underrepresented in phase 1 and 2 clinical trials.